Posts Tagged ‘otc’

Cord Blood America Says Two Recent Financial Transactions Strengthen Company’s Balance Sheet

In BUSINESS OF STEM CELLS on August 6, 2010 at 12:55 pm

(OTCBB: CBAI – Cord Blood America, Inc.)


LATEST NEWS!! Cord Blood America Says Two Recent Financial Transactions Strengthen Company’s Balance Sheet

LAS VEGAS, Aug 05, 2010 — Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today said that it has had positive movement on two financial obligations that further strengthen its balance sheet.

The Company announced it has retired a $1.1 million debt obligation with JMJ Financial. “Eliminating debt and getting to cash flow positive are paramount to the long term success of CBAI,” said Matthew Schissler, co-founder and CEO. “We are laser focused on these two goals.” Also, in a Form 8-K filing, Cord Blood America announced, after extensive negotiations, it has canceled a 36 million share Warrant Agreement valued at $1.8 million with Shelter Island Opportunity Fund, LLP, and replaced it with a Senior Secured Note in the principal amount of $1,590,400.

“This obligation was under the derivative liability line on our balance sheet, and as a result, now gets paid down over the next 12 months, making our balance sheet stronger. We took 36 million warrants off the table. The obligation in total was reduced by over $300,000 by our calculations. Interest is only for 6 months and payable in cash. We believe reducing the principal and interest obligation, removing warrant overhang, reducing the derivative liability over the next 12 months are all good for shareholders,” said Matthew Schissler, co-founder and CEO. “It is important that our shareholders understand that we are continually working to improve our financial condition, as well as acquiring new businesses and diversifying our revenue stream.” About Cord Blood America Cord Blood America is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc., visit our website at http://www.corcell.com/.

via www.StockMarketingInc.com: Stock Marketing Inc Presents!! ERFW,ADLS,ELRA,CBAI,VKNG,WSRA:: Sign Up With Us Today!! | TradingMarkets.com.


In ALL ARTICLES on February 20, 2010 at 11:43 pm



For six years, the American people’s understanding of stem cells has been overwhelmed by rampant misinformation and deception. We were led to believe the future of medicine lies in Embryonic Stem Cells (ESC) and that Repair (adult) Stem Cells (RSC) are “snake oil.”
These skewed stories of ESC hope and RSC failure intentionally misled the American people in general and forced spinal cord patients to pay for the false-hope of ESC treatments in order to line the pockets of the  ESC promoters.



In BUSINESS OF STEM CELLS on November 15, 2009 at 11:30 pm


BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), a leading developer of adult stem cell technologies and therapeutics, is pleased to announce that its chief medical advisor, Professor Eldad Melamed, was interviewed on November 9, 2009 on Israel?s most popular radio broadcast, Galei Zahal. The interview was conducted by Yaron Willensky, a respected news talk show host, to discuss the latest achievements, treatment and progress of BrainStorm?s stem cell technology and therapy with respect to neurodegenerative diseases such as ALS and Parkinson?s disease.

?The stem cell therapy treatment is ready. We have successfully been able to process autologous adult human mesenchymal stem cells, grow them and differentiate them into other cell types for the treatment of neurodegenerative diseases. We are currently in middle of obtaining approval to begin the first clinical trials on ALS patients in Israel,? stated Professor Melamed during the interview. ?Regarding clinical trials for Parkinson?s disease, we are ready to begin,? continued Professor Melamed. ?However, we must still complete the regulatory approval process before that can happen.?


BrainStorm Reschedule Webcast Audio Conference

In BUSINESS OF STEM CELLS on October 15, 2009 at 12:27 pm

NEW YORK & PETACH TIKVAH, Israel–(Business Wire)– BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI – News) , announced today that it will reschedule the webcast audio conference to update shareholders on its strategy and report on the way forward towards clinical trials. This event will be rescheduled for a later date to be announced soon. We apologize for any inconvenience.

via BrainStorm Announces That It Will Reschedule Its Webcast Audio Conference | Reuters.


Aastrom requests delisting extension

In BUSINESS OF STEM CELLS on October 8, 2009 at 3:19 pm

Aastrom Biosciences Inc. will request hearing to avoid Nasdaq delisting – By Gabe Nelson


Aastrom is a leader in regenerative medicine developing autologous cell products for the treatment of chronic cardiovascular diseases.

Ann Arbor-based Aastrom Biosciences Inc. (Nasdaq: ASTM) is in danger of being removed from the Nasdaq Stock Exchange because the company’s stock price has remained below the listing threshold of $1, the company said today.

Aastrom plans to request a hearing with Nasdaq by Oct. 13 to request an extension, according to a statement.

Aastrom produces stem cell-based therapeutics to repair human tissue. The stem cells, grown from a patient’s bone marrow, are used to treat conditions such as chronic cardiovascular diseases.

The company first faced delisting in December 2007 and received a 180-day extension the following June.

Though Aastrom’s stock price stayed below $1, the company remained listed because of a temporary change to Nasdaq policy. The exchange suspended threshold requirements from last October until this July because so many companies saw their stock fall below $1 during the recession.

The most recent extension, granted in July, gave Aastrom until Oct. 1.

The exchange could choose to grant Aastrom an additional 180 days, or until March 31, 2010, to meet listing criteria.

The company’s stock price would need to close at $1 or above for 10 consecutive days of trading.

It opened Wednesday at 42 cents.

via Aastrom Biosciences Inc. will request hearing to avoid Nasdaq delisting – Detroit News and Information – Crain’s Detroit Business.


In BUSINESS OF STEM CELLS on September 28, 2009 at 4:04 pm

SWVL, EVFL, GOIG, SCII, September 28 Stocks to Watch from otcpicks.com

Emailwire – ‎7 hours ago‎
Stem Cell Therapy International, Inc., through its wholly owned subsidiary, Stem Cell Therapy International Corp., engages in licensing of stem cell

Not knowing what’s ahead, we look to futurists to help figure it out

Philadelphia Inquirer – Carol M. Ostrom – ‎6 hours ago‎
Dr. Chuck Murry, a University of Washington researcher who works with heart muscles and stem cells, doesn’t call himself a futurist, but adds: “I think we

Merkel wins German election

Nature.com (subscription) – ‎9 hours ago‎
[The Free Democrats] have a distinctly liberal approach in hot-button areas such as genetically modified crops and stem cells. … If the Free Democrats,

2009 Annual Financial Report

Sydney Morning Herald – ‎11 hours ago‎
Biocell was subsequently renamed Australian Stem Cell Healthcare Pty Ltd and is now the largest private cord blood bank in Australia.

Primera Bioscience Research Inc. Announces 2009 Financing

PR-USA.net (press release) – ‎10 hours ago‎
The Corporation currently has one project which is to collaborate with and provide $300000 of funding for certain brain tumour and stem cell research being

Dr. Stockpick Announces Daily Stock Watch – GFGU, PWRM, SCII

World Stock Wire (press release) – ‎8 hours ago‎
Today’s alerts include: getfugu, Inc. (OTCBB: GFGU), Power3 Medical Products, Inc. (OTCBB: PWRM), and Stem Cell Therapy International, Inc. (OTCBB: SCII).

BUYINS.NET: Naked Short Web Site Announces DNE, OSIR, GBGD Have

Trading Markets (press release) – ‎5 hours ago‎

There is no longer a failure to deliver in shares of DNE Osiris Therapeutics, Inc. (NASDAQ: OSIR), a stem cell therapeutic company, develops products to

Advanced Cell Technology Announces Proxy Results | Reuters

In BUSINESS OF STEM CELLS on September 16, 2009 at 2:33 pm

WORCESTER, Mass.–(Business Wire)– Advanced Cell Technology, Inc. (Advanced Cell, ACT) (OTC: ACTC) announced today that shareholders have approved each proposal in the Company`s proxy statement dated August 5, 2009.

As a result, the 2005 Stock Incentive Plan has been amended to increase the total number of shares available for issuance and the certificate of incorporation has been amended to increase the authorized shares eligible for issuance by the Company.

“We are pleased that shareholders have elected to approve each of the proposals in the proxy, supporting the Company`s efforts to further develop its stem cell technology platform,” said William M. Caldwell IV, the Company`s Chairman and Chief Executive Officer.

“We remain focused on submitting an IND for the RPE program to the FDA for approval to commence a Phase I Clinical Trial prior to the end of the year.”

via Advanced Cell Technology Announces Proxy Results | Reuters.

Are you or a loved one interested in receiving stem cell treatment? For free treatment information, please fill out our treatment form or email don@repairstemcells.org and just put Therapy in the subject box.

AMIE,DSCO,SPDE,SCII OTC Picks Sept 14 – Stocks to Watch

In BUSINESS OF STEM CELLS on September 14, 2009 at 6:28 pm

STEM CELL THERAPY INTERNATIONAL (OTCBB: SCII | Quote | Chart | News | PowerRating) “Up 69.81% on Friday”

Detailed Quote: http://www.otcpicks.com/quotes/SCII.php

Stem Cell Therapy International, Inc., through its wholly owned subsidiary, Stem Cell Therapy International Corp., engages in licensing of stem cell technology and the sale of stem cell products, as well as the provision of information, education, and referral services. It provides allo stem cell biological solutions that are used in the treatment of patients suffering from degenerative disorders of the human body, such as Alzheimer's Disease, Parkinson's Disease, ALS, leukemia, muscular dystrophy, multiple sclerosis, arthritis, spinal cord injuries, brain injury, stroke, heart disease, liver and retinal disease, and diabetes, as well as certain types of cancer. The company's stem cell biological solutions can be used to alleviate the side effects of chemotherapy

. Its principal stem cell products are solutions containing allo stem cell biological solutions, either adult stem cells, and stem cells that are extracted from umbilical cord blood. It intends to offer biological solutions containing stem cell products primarily in the United States to universities, institutes, and privately funded laboratory facilities for research purposes and clinical trials. The company was incorporated in 2004 and is headquartered in Tampa, Florida.

via AMIE,DSCO,SPDE,SCII OTCPicks.com: AMIE, DSCO, SCII, SPDE, September 14 Stocks to Watch from OTCPicks.com.

GCKO,GVBP,NPDT,OGNG Wall Street News Alert

In BUSINESS OF STEM CELLS on September 14, 2009 at 11:06 am

GENova Biotherapeutics

GENova Biotherapeutics, Inc. (OTCBB: GVBP | Quote | Chart | News | PowerRating) up 17.8% on 39 million shares traded.

breast reconstructionOn Sept 10, 2009 GENova Biotherapeutics, Inc. a biotechnology company that identifies, acquires, and develops novel drug targets that disrupt the advance of life-threatening diseases, recently announced it has filed a patent for a potential blockbuster drug target that combats breast cancer. The target, Tetanolic acid, is a tailor-made lipid which induces cell death in breast cancer cells, thus curtailing development of the harmful cancer.

breast cancer cell

breast cancer cell

This novel approach – using proteins to stop cancer – is based on recent discoveries that indicate that most tumors are derived from a cancer stem cell. The technology behind Tetanolic acid involved identifying specific characteristics of these cancer stem cells and then tailoring a lipid (Tetanolic acid) that can identify these characteristics and then attack the malignant cells whilst leaving healthy cells intact. This tailor-made cancer treatment strategy is far superior to any existing therapies, as it terminates the cancer at the source, with no side effects, and no harm to surrounding healthy tissues.



“This target has tremendous market potential, as it can ultimately eliminate the need for surgery and chemotherapy,” says Aaron Whiteman for GENova.

Worldwide, breast cancer is the fifth most common cause of cancer death, and is the most common cancer (and cause of cancer death) in women. The demand for new and better treatments for the disease is as urgent as ever.

via GCKO,GVBP,NPDT,OGNG Wall Street News Alert: Stock on the Move: GCKO – September 10, 2009.

BCLI,CVIT,CVITE,NWMT,NPHC – NewMarket Technology – September 2, 2009

In BUSINESS OF STEM CELLS on September 3, 2009 at 10:24 am

Weston, FLA, Sep 02, 2009 (M2 PRESSWIRE via COMTEX) — NPHC | Quote | Chart | News | PowerRating — Wall Street News Alert's “stocks to watch” this morning are: NewMarket Technology, Inc. (OTC: NWMT), Cavit Sciences Inc. (OTC: CVIT), BrainStorm Cell Therapeutics Inc (OTCBB: BCLI | Quote | Chart | News | PowerRating) and Nutra Pharma Corp. (OTCBB: NPHC).

via BCLI,CVIT,CVITE,NWMT,NPHC Wall Street News Alert: Stock Watch for Wednesday: NewMarket Technology – September 2, 2009.

%d bloggers like this: